Place of tiotriazoline in the gallery of modern metabolitotropic medicines

Abstract

We want to show pharmacological characterization of Tiotriazoline, based on results of tentative analysis and clinical research, also features of its therapeutic action and advantage over another metabolitotropic cardio protectors. As a result of the literary sources

Mitochondrial dysfunctions and antihypoxants

“…Thiotriazoline influences the opening of the cyclosporine-A-dependent pore, saves the mitochondrial membrane charge, increases the level of heat shock protein HSP70 in the mitochondria. The use of thiotriazoline in clinic practice demonstrated its effectiveness in secondary MD, where it improved the quality and life expectancy of patients with myocardial infarction, chronic heart failure, after myocardial remodeling [9]. Thiotriazoline is indicated in the complex therapy of MELAS syndrome in cardiomyopathy, as well as in the therapy of the metabolic stroke [18].…”

Therapy of post-COVID-19 syndrome: improving the efficiency and safety of basic metabolic drug treatment with tiazotic acid (thiotriazoline)

“…Thiotriazoline increases the level of reduced glutathione, which regulates the Red/Oxi mechanisms of expression of genes responsible for the synthesis of enzymes, including those that regulate pro-inflammatory cascades -lipoxygenase and cyclooxy-genase. Thiotriazoline can directly participate in the regulation of transcriptional activity, prevents the development of imbalance in the thiosulfide system during hyperproduction of ROS, providing such functions as transmission of the cellular signal through the receptor-ionophore complex, preserving the activity of proteins, enzymes, transcription factors and cell integrity (Belenichev et al 2007(Belenichev et al , 2019. There is evidence that thiotriazoline exhibits immunomodulatory activity, increasing the level of interferon, as well as increasing the number of T-lymphocytes.…”

“…The very interesting effects of thiotriazoline include its protective effect on the vascular endothelium, which is of great importance in COVID-19, since endothelial dysfunction inevitably develops in this pathology. It is noted that the formation of endothelial dysfunction in COVID-19 occurs more rapidly in elderly patients taking ACE inhibitors (Belenichev et al 2008(Belenichev et al , 2019. Endothelial dysfunction is a predictor of such formidable diseases as strokes and myocardial infarctions.…”

“…We have obtained preliminary encouraging results on the positive effect of Tiazotic acid in COVID-19 (Kryvenko et al 2021). Given the cardiovascular complications caused by both the coronavirus itself and the drugs used in the treatment of COVID-19, data on the cardioprotective effect of thiotriazoline obtained in a number of preclinical and clinical studies (Mazur et al 2007;Belenichev et al 2019. Thiotriazoline reduces mortality, improves ECG, reduces the area of necrosis in experimental myocardial infarction.…”

“…The drug prevents the destruction of hepatocytes, reduces the degree of fatty infiltration and the spread of centrilobular necrosis of the liver, promotes reparative regeneration of hepatocytes, normalizes their protein, carbohydrate, lipid and pigment metabolism. Increases the rate of synthesis and excretion of bile, normalizes its chemical composition (Mazur et al 2007;Belenichev et al 2019).…”